Testing for Tweet Capability

Testing Tweet

How to Decide to Offer a New Lab Test

Jared N. Schwartz, MD PhD LLC Past President, College of American Pathologists; Opinions his own; Charlotte, NC Q: Pathologists are faced with the need to set up additional lab tests routinely. Immunotherapy for cancer is the current rage. How does a pathologist decide whether and how to offer a new test such as PD-L1 Expression […]

Preventing Hair Loss from Cancer Chemotherapy

Richard B. Schwab, MD. Associate Clinical Professor of Medicine, Moores Cancer Center, University of California, San Diego, School of Medicine Q: Loss of hair is a predictable adverse effect of much chemotherapy. Although “only cosmetic” this can be a troubling event for some patients. What is your opinion about the new devices or methods available […]

Mutational Oncology: The Basics

Vivian B. Douglas, PhD. Associate Knowledge Engineer, CollabRx San Francisco, California Q: Many mature clinicians find “Mutational Oncology” to be a bit mysterious. Please help them understand. As they pertain to cancer, what are somatic (as opposed to germ line) mutations, transitions, transversions, “point”, “missense”, “nonsense”, insertion, deletion, and copy numbers and why does it […]

The Most Relied Upon Journals in Precision Oncology

Q: The medical world is running amuck with new info, some credible, some not. What are the most reliable sources of information in Precision Oncology?

Length and Quality of Life in Cancer Patient Treatment

Professor Michael Baum, Professor Emeritus of Surgery & Visiting Professor of Medical Humanities. University College, London, UK Q: Although you have practiced as a surgeon in the British National Health Service (NHS) for most of your career, how is it that you’ve been such an outspoken critic of the “21st C cures act” that was […]

Canadian/American Cancer

Cynthia Martin, MA is a freelance/ghost writer (who tried to write a serious piece). Q: As a journalist, you are a savvy native Canadian consumer/patient who also knows a lot about the United States. What do you see as the main similarities and differences between cancer prevention and care in the US and Canada? A: […]

Conflict of Interest in Cancer Clinical Trials

Kevin B. Knopf, MD MPH, Medical Director, Cancer Commons San Francisco, California Q: Clinical trials are the lifeblood of continuing drug development in the US. Yet they are often undersubscribed. What do you see as key conflicts of interest in recruiting for patients in the academic medical center, the hospital, and the private oncologists’ practice? […]